Tofogliflozin attenuates liver steatosis and fibrosis in non-diabetic non-alcoholic steatohepatitis mice
Tofo may be a potential candidate for inhibiting liver steatosis and fibrosis via an alternative pathway, unlike glucose metabolism, in NAFLD patients without diabetes.
Authors
- Satoru Hasuike (ORCID: https://orcid.org/0000-0002-5312-5152)
- Keisuke Uchida
- Yoshinori Ozono
- Hiroshi Kawakami (ORCID: https://orcid.org/0000-0003-0969-366X)
- Hiroshi Hatada
- Hisayoshi Iwakiri
- Yuri Komaki
- Naomi Uchiyama
- Hotaka Tamura
- Kenji Nagata
Institutions
- University of Miyazaki (JP)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1186/s12876-026-04610-1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00